Health Canada on track to approve AstraZeneca COVID-19 vaccine by mid-February - CTV News | Canada News Media
Connect with us

Business

Health Canada on track to approve AstraZeneca COVID-19 vaccine by mid-February – CTV News

Published

 on


OTTAWA —
Health Canada is on track to give the green light to a third COVID-19 vaccine within the next two weeks and a fourth may not be far behind, offering a glimmer of hope at the end of a week of nothing but vaccine vexation.

Eric Morrissette, chief of media relations at Health Canada, said Friday the regulatory team that has been reviewing an application from AstraZeneca since Oct. 1 is just awaiting final submissions from the drugmaker on manufacturing processes before making its decision.

AstraZeneca was the first to apply for approval for a COVID-19 vaccine in Canada and has been greenlit in 15 jurisdictions including the United Kingdom, Mexico, India, and as of Friday, the entire European Union.

Dr. Supriya Sharma, Health Canada’s chief medical adviser, said earlier this month the review was “a bit more complicated” because in AstraZeneca’s trials, some volunteers only received a half dose at first.

A big trial underway in the United States is supposed to provide more clarity, but Morrissette said Friday that trial won’t report findings until March and Health Canada’s team has decided it has all the clinical data it needs.

A fourth vaccine could be close at hand as well, after Johnson and Johnson reported Friday that Phase 3 clinical trial results – typically the last before a drug is approved for wide use – showed its vaccine is about 85 per cent effective against serious illness from COVID-19. Johnson and Johnson, which submitted an application to Canada for approval Nov. 30, offers the only single-dose vaccine thus far.

Health Canada approved Pfizer-BioNTech’s vaccine on Dec. 9. and Moderna’s on Dec. 23, each time about three weeks after Phase 3 trial results were publicly reported.

Canada has pre-ordered 10 million doses from Johnson and Johnson with the potential to get 28 million more, and 20 million doses from AstraZeneca. But the federal government has not said when those doses would be delivered, and recent days have shown deliveries for COVID-19 vaccines are constantly subject to change.

Moderna became the third vaccine-maker in two weeks Friday, to announce production delays will cut into its upcoming deliveries.

The Massachusetts-based biotech firm shipped more than 340,000 doses to Canada in the last month, but next week’s shipment is getting cut by about one-fifth, or 50,000 fewer doses, because of slower-than-expected production of the drug components by Moderna’s manufacturing partner, Lonza. Similar reductions are affecting Europe.

Moderna’s Canadian country manager Patricia Gauthier said the company will ship all two millions doses its contract stipulates by the end of March. Canada bought 40 million doses from Moderna overall, with most of them contracted to arrive between April 1 and Sept. 30.

Canada’s budding vaccination effort shrivelled this week when a temporary production slowdown caused Pfizer and BioNTech to cancel an entire shipment of more than 208,000 doses, after cutting last week’s shipment by about 20 per cent. The next two weeks’ deliveries will be cut by about 80 per cent before mostly being restored the week of Feb. 15.

Pfizer is also now asking Canada to agree each of its vials contains six doses, rather than five, which would allow it to ultimately ship fewer vials to meet its obligation of four million doses by the end of March, and 40 million by the fall.

AstraZeneca is cutting deliveries to Europe by 60 per cent through the end of March because of production problems in Belgium. That, coupled with Pfizer’s delays, prompted the European Union to require vaccine makers to report on how many doses are being produced and exported from Europe.

All of Canada’s Pfizer and Moderna vaccine doses are made in Europe. Canadian officials won’t say where Canada’s doses from AstraZeneca are to be made, but insist they will be unaffected by the European production problems.

Canada is not among more than 120 countries exempted on paper from the export controls, but Prime Minister Justin Trudeau said European Commission President Ursula von der Leyen assured him in a phone call Wednesday that the export controls won’t affect Canada.

Despite the production hiccups, Trudeau insisted Friday Canada’s vaccine program is on track, noting production problems when the world is trying to build manufacturing lines for new products in massive demand are not a surprise.

Canada’s current vaccination plan says there will be three million people vaccinated by the end of March and another 10 million by the end of June, and that anyone else who wants to be immunized will be by the end of September.

Conservative Leader Erin O’Toole said the government needs to be more transparent about its vaccine contracts. Canada has contracts with seven COVID-19 vaccine-makers but has never published any details, including prices or delivery timelines.

The United States released redacted versions of contracts it has, and the European Commission Friday released a redacted AstraZeneca contract and said it wants to release the rest as soon as possible. It has to negotiate doing so with the companies.

Trudeau said Friday Canada will try to do that too but won’t jeopardize getting vaccines to Canadians as quickly as possible.

This report by The Canadian Press was first published Jan. 29, 2021

Let’s block ads! (Why?)



Source link

Continue Reading

Business

Roots sees room for expansion in activewear, reports $5.2M Q2 loss and sales drop

Published

 on

 

TORONTO – Roots Corp. may have built its brand on all things comfy and cosy, but its CEO says activewear is now “really becoming a core part” of the brand.

The category, which at Roots spans leggings, tracksuits, sports bras and bike shorts, has seen such sustained double-digit growth that Meghan Roach plans to make it a key part of the business’ future.

“It’s an area … you will see us continue to expand upon,” she told analysts on a Friday call.

The Toronto-based retailer’s push into activewear has taken shape over many years and included several turns as the official designer and supplier of Team Canada’s Olympic uniform.

But consumers have had plenty of choice when it comes to workout gear and other apparel suited to their sporting needs. On top of the slew of athletic brands like Nike and Adidas, shoppers have also gravitated toward Lululemon Athletica Inc., Alo and Vuori, ramping up competition in the activewear category.

Roach feels Roots’ toehold in the category stems from the fit, feel and following its merchandise has cultivated.

“Our product really resonates with (shoppers) because you can wear it through multiple different use cases and occasions,” she said.

“We’ve been seeing customers come back again and again for some of these core products in our activewear collection.”

Her remarks came the same day as Roots revealed it lost $5.2 million in its latest quarter compared with a loss of $5.3 million in the same quarter last year.

The company said the second-quarter loss amounted to 13 cents per diluted share for the quarter ended Aug. 3, the same as a year earlier.

In presenting the results, Roach reminded analysts that the first half of the year is usually “seasonally small,” representing just 30 per cent of the company’s annual sales.

Sales for the second quarter totalled $47.7 million, down from $49.4 million in the same quarter last year.

The move lower came as direct-to-consumer sales amounted to $36.4 million, down from $37.1 million a year earlier, as comparable sales edged down 0.2 per cent.

The numbers reflect the fact that Roots continued to grapple with inventory challenges in the company’s Cooper fleece line that first cropped up in its previous quarter.

Roots recently began to use artificial intelligence to assist with daily inventory replenishments and said more tools helping with allocation will go live in the next quarter.

Beyond that time period, the company intends to keep exploring AI and renovate more of its stores.

It will also re-evaluate its design ranks.

Roots announced Friday that chief product officer Karuna Scheinfeld has stepped down.

Rather than fill the role, the company plans to hire senior level design talent with international experience in the outdoor and activewear sectors who will take on tasks previously done by the chief product officer.

This report by The Canadian Press was first published Sept. 13, 2024.

Companies in this story: (TSX:ROOT)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Talks on today over HandyDART strike affecting vulnerable people in Metro Vancouver

Published

 on

 

VANCOUVER – Mediated talks between the union representing HandyDART workers in Metro Vancouver and its employer, Transdev, are set to resume today as a strike that has stopped most services drags into a second week.

No timeline has been set for the length of the negotiations, but Joe McCann, president of the Amalgamated Transit Union Local 1724, says they are willing to stay there as long as it takes, even if talks drag on all night.

About 600 employees of the door-to-door transit service for people unable to navigate the conventional transit system have been on strike since last Tuesday, pausing service for all but essential medical trips.

Hundreds of drivers rallied outside TransLink’s head office earlier this week, calling for the transportation provider to intervene in the dispute with Transdev, which was contracted to oversee HandyDART service.

Transdev said earlier this week that it will provide a reply to the union’s latest proposal on Thursday.

A statement from the company said it “strongly believes” that their employees deserve fair wages, and that a fair contract “must balance the needs of their employees, clients and taxpayers.”

This report by The Canadian Press was first published Sept. 12, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Transat AT reports $39.9M Q3 loss compared with $57.3M profit a year earlier

Published

 on

 

MONTREAL – Travel company Transat AT Inc. reported a loss in its latest quarter compared with a profit a year earlier as its revenue edged lower.

The parent company of Air Transat says it lost $39.9 million or $1.03 per diluted share in its quarter ended July 31.

The result compared with a profit of $57.3 million or $1.49 per diluted share a year earlier.

Revenue in what was the company’s third quarter totalled $736.2 million, down from $746.3 million in the same quarter last year.

On an adjusted basis, Transat says it lost $1.10 per share in its latest quarter compared with an adjusted profit of $1.10 per share a year earlier.

Transat chief executive Annick Guérard says demand for leisure travel remains healthy, as evidenced by higher traffic, but consumers are increasingly price conscious given the current economic uncertainty.

This report by The Canadian Press was first published Sept. 12, 2024.

Companies in this story: (TSX:TRZ)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending

Exit mobile version